GlassScriptPhysician profile
Melissa Duchene
NPI 1710556063
$4,097.82
in general payments reported to CMS, 2019-2025
36 companies · $77.95 in 2025
The $77.95 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $2,516 · 2023: $613 · 2025: $77.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.48 | 2021-2023 | |
| Emd Serono, INC. | $345.42 | 2022-2023 | Mavenclad |
| Amgen INC. | $300.39 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $276.29 | 2021-2022 | |
| Celgene Corporation | $251.64 | 2021-2025 | Breyanzi, Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $249.42 | 2022 | |
| Ucb, INC. | $235.22 | 2021-2022 | |
| Lilly USA, LLC | $186.82 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $170.77 | 2021 | |
| Kyowa Kirin, INC. | $154.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $133.95 | 2022 | |
| Biogen, INC. | $117.27 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $97.05 | 2023 | Libtayo |
| Lundbeck LLC | $96.21 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $83.00 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $81.84 | 2022 | |
| Acorda Therapeutics, INC | $78.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $71.42 | 2021-2022 | |
| Sk Life Science, INC. | $53.90 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $45.84 | 2022 | |
| Argenx US, INC. | $36.25 | 2022 | |
| Insightec,INC | $30.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.37 | 2021 | |
| Genzyme Corporation | $26.46 | 2022 | |
| Beone Medicines USA, INC. | $24.96 | 2025 | Brukinsa |
| Alnylam Pharmaceuticals INC. | $22.71 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.47 | 2021 | |
| Genentech USA, INC. | $18.89 | 2022 | |
| Allergan, INC. | $18.52 | 2021 | |
| Avion Pharmaceuticals | $18.46 | 2022 | |
| Medtronic, INC. | $18.05 | 2022 | |
| Livanova USA, INC. | $17.99 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.50 | 2022 | |
| Neurelis, INC. | $17.01 | 2022 | |
| Tanabe Pharma America, INC. | $16.72 | 2022 | |
| Eisai INC. | $15.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Duchene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.